# Platelet Inhibition to Target Reperfusion Injury

Study · id `cardio:ct-nct03102723` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03102723](<https://clinicaltrials.gov/study/NCT03102723>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03102723

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 228 participants.

## Technical summary

Registry record NCT03102723. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-01 (actual); primary completion 2022-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 228 participants (enrolled count; ClinicalTrials.gov record NCT03102723, source copy `cardio:ctgov-nct03102723-2022-04-26`, retrieved 2026-10-26)
- Started: 2017-10-01 (actual) (ClinicalTrials.gov record NCT03102723, source copy `cardio:ctgov-nct03102723-2022-04-26`, retrieved 2026-10-26)
- Primary completion: 2022-12 (anticipated) (ClinicalTrials.gov record NCT03102723, source copy `cardio:ctgov-nct03102723-2022-04-26`, retrieved 2026-10-26)
- Completion: 2022-12 (anticipated) (ClinicalTrials.gov record NCT03102723, source copy `cardio:ctgov-nct03102723-2022-04-26`, retrieved 2026-10-26)
- Countries: Singapore (ClinicalTrials.gov record NCT03102723, source copy `cardio:ctgov-nct03102723-2022-04-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03102723-2022-04-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Platelet Inhibition to Target Reperfusion Injury
- Acronym: PITRI
- Condition: STEMI
- Intervention (Drug): Cangrelor
- Lead sponsor: National Heart Centre Singapore
- Lead sponsor class: OTHER
- Collaborator: Tan Tock Seng Hospital
- Collaborator class: OTHER
- Collaborator: National University Hospital, Singapore
- Collaborator class: OTHER
- Collaborator: Khoo Teck Puat Hospital
- Collaborator class: OTHER
- Collaborator: Changi General Hospital
- Collaborator class: OTHER
- Collaborator: Sengkang General Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: National Heart Centre Singapore (`cardio:org-national-heart-centre-singapore`)
- Registry lists this organization as a collaborator: Tan Tock Seng Hospital (`cardio:org-tan-tock-seng-hospital`)
- Registry lists this organization as a collaborator: National University Hospital, Singapore (`cardio:org-national-university-hospital-singapore`)
- Registry lists this organization as a collaborator: Khoo Teck Puat Hospital (`cardio:org-khoo-teck-puat-hospital`)
- Registry lists this organization as a collaborator: Changi General Hospital (`cardio:org-changi-general-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial) (`cardio:pubmed-38742915`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 33356794cf2bec3cbf10656bce1b3fe0721f7d9f96d8b553f6de359e69f05c33
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
